Last ¥11,900 JPY
Change Today +190.00 / 1.62%
Volume 366.4K
4528 On Other Exchanges
Symbol
Exchange
Munich
Tokyo
OTC US
OTC US
As of 1:00 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

ono pharmaceutical co ltd (4528) Snapshot

Open
¥11,860
Previous Close
¥11,710
Day High
¥12,130
Day Low
¥11,840
52 Week High
01/21/15 - ¥12,800
52 Week Low
05/21/14 - ¥7,710
Market Cap
1.4T
Average Volume 10 Days
280.2K
EPS TTM
--
Shares Outstanding
117.8M
EX-Date
03/27/15
P/E TM
--
Dividend
¥180.00
Dividend Yield
1.51%
Current Stock Chart for ONO PHARMACEUTICAL CO LTD (4528)

Related News

No related news articles were found.

ono pharmaceutical co ltd (4528) Related Businessweek News

No Related Businessweek News Found

ono pharmaceutical co ltd (4528) Details

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents in Japan and internationally. Its products primarily include Rivastach Patch to treat Alzheimer's disease; Glactiv and FORXIGA tablets for the treatment of type II diabetes; Emend capsules/Proemend Intravenous injection for chemotherapy-induced nausea and vomiting; Recalbon tablets to treat osteoporosis; Staybla tablets for the treatment of overactive bladder; Opalmon tablets for peripheral circulatory disorder; and Onon capsules for the treatment of bronchial asthma and allergic rhinitis. The company’s products also comprise Onon dry syrup for the treatment of bronchial asthma and allergic rhinitis; Kinedak tablets for the treatment of diabetic peripheral neuropathy; Foipan tablets for the treatment of chronic pancreatitis and postoperative reflux esophagitis; Elaspol injection for the treatment of acute lung injury associated with systemic inflammatory response syndrome; Onoact injection for the treatment of tachyarrhythmia; and ORENCIA injection for the treatment of rheumatoid arthritis. In addition, it is involved in developing drugs for various indications, such as melanoma, renal cell carcinoma, non-small cell lung cancer, bronchial asthma, allergic rhinitis, irritable bowel syndrome, glaucoma, ocular hypertension, B-cell lymphoma, underactive bladder, gastroesophageal reflux disease, Parkinson’s disease, portal hypertension, acute heart failure, head and neck carcinoma, glioblastoma, diffuse large b cell lymphoma, follicular lymphoma, chronic myeloid leukemia, and juvenile idiopathic arthritis, as well as esophageal, ovarian, and colon cancer. Ono Pharmaceutical Co., Ltd. has drug discovery strategic alliances with Array BioPharma Inc.; Locus Pharmaceuticals, Inc.; BioSeek LLC; Receptos Inc.; Xention Limited; BioFocus DPI Limited; Evotec AG; Scil Proteins GmbH; and Domain Therapeutics S.A. The company was founded in 1717 and is headquartered in Osaka, Japan.

2,858 Employees
Last Reported Date: 06/30/14
Founded in 1717

ono pharmaceutical co ltd (4528) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ono pharmaceutical co ltd (4528) Key Developments

Dako and ONO PHARMACEUTICAL CO., LTD. Announce Collaboration on Development of PD-L1 Companion Diagnostic Test for Investigational Cancer Drug Opdivo(R)

Dako and ONO PHARMACEUTICAL CO., LTD. announced a new partnership to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer (NSCLC). This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo.

Ono Pharmaceutical Co., Ltd. Announces Unaudited Consolidated Earnings Results for Nine Months Ended December 31, 2014; Revises Earnings Guidance for the Full Year Ending March 31, 2015

Ono Pharmaceutical Co., Ltd. announced unaudited consolidated earnings results for nine months ended December 31, 2014. For the period, the company reported revenue of ¥107,267 million, operating profit of ¥16,474 million, profit before tax of ¥19,799 million, profit attributable to owners of the parent company of ¥15,708 million or ¥148.17 per basic share, net cash provided by operating activities of ¥7,121 million, purchases of property, plant and equipment of ¥12,109 million and purchases of intangible assets of ¥13,420 million compared to the revenue of ¥111,424 million, operating profit of ¥25,590 million, profit before tax of ¥28,715 million, profit attributable to owners of the parent company of ¥19,883 million or ¥187.55 per basic share, net cash provided by operating activities of ¥17,145 million, purchases of property, plant and equipment of ¥2,917 million and purchases of intangible assets of ¥6,802 million for the same period a year ago. The company revised earnings guidance for the full year ending March 31, 2015. For the year, the company expects revenue of ¥137,000 million, operating profit of ¥15,100 million, profit before tax of ¥17,700 million and profit attributable to owners of the company of ¥12,000 million or ¥113.20 per basic share. The forecasts for the year ending March 31, 2015 are revised from November 5, 2014 for the reasons: The company has estimated royalty income which had not originally been expected in its forecasts announced on November 5, 2014. On the other hand, the company will not recognize a reduction of past service cost in fourth quarter due to a delay in pension scheme alteration, which will have retirement benefit expenses increased.

Ono Pharmaceutical Co. Ltd. and Gilead Sciences Inc. Enters into Exclusive License Agreement for the Development and Commercialization of ONO-4059

Ono pharmaceutical co. ltd. and Gilead Sciences Inc. (GILD) entered into an exclusive license agreement for the development and commercialization of ONO-4059, ONO's oral Bruton's tyrosine kinase or BTK inhibitor for the treatment of B-cell malignancies and other diseases. As per the terms of the agreement, Gilead will pay ONO an upfront payment plus additional payments based upon achievement of certain development, regulatory and commercial milestones. The companies will collaborate jointly on global development of ONO-4059. Gilead will have exclusive rights to develop and commercialize ONO-4059 in all countries of the world outside of Japan, South Korea, Taiwan, China and the Association of Southeast Asian Nations (ASEAN) countries, where ONO retains development and commercialization rights. ONO-4059 is a selective, once-daily, oral inhibitor of BTK, which has been shown to play a role in the survival and proliferation of malignant B-cells. ONO has presented preliminary Phase 1 data showing clinical activity in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) at several scientific conferences. ONO and Gilead plan to develop ONO-4059 for the treatment of B-cell malignancies and other diseases as a monotherapy and in combination with approved and investigational agents, including combinations with kinase inhibitors in Gilead's portfolio.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4528:JP ¥11,900.00 JPY +190.00

4528 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4528.
View Industry Companies
 

Industry Analysis

4528

Industry Average

Valuation 4528 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONO PHARMACEUTICAL CO LTD, please visit www.ono.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.